Published in Blood on September 30, 2014
An update of current treatments for adult acute myeloid leukemia. Blood (2015) 1.23
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2016) 1.05
Molecular Genetic Markers in Acute Myeloid Leukemia. J Clin Med (2015) 0.88
Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol (2015) 0.86
'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J (2016) 0.86
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discov (2016) 0.84
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant (2015) 0.83
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia (2016) 0.81
Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transplant (2015) 0.79
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget (2015) 0.79
Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia (2016) 0.79
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. Oncotarget (2015) 0.78
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematologica (2016) 0.78
Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32). PLoS One (2015) 0.77
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia (2017) 0.77
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol (2016) 0.76
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant (2016) 0.76
Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. Leukemia (2017) 0.76
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis. Biomark Insights (2015) 0.75
FLT3 inhibitors: clinical potential in acute myeloid leukemia. Onco Targets Ther (2017) 0.75
Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia. Leukemia (2015) 0.75
Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol (2017) 0.75
Allelic ratio: a marker of clonal dominance. Blood (2014) 0.75
Molecular landscape in acute myeloid leukemia: where do we stand in 2016. Cancer Biol Med (2016) 0.75
Allogeneic transplant for FLT3-ITD+ AML: room for improvement. Bone Marrow Transplant (2016) 0.75
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res (2015) 0.75
Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene (2015) 0.75
Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation. Leuk Res (2015) 0.75
How I treat FLT3-mutated AML. Blood (2016) 0.75
Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. Haematologica (2016) 0.75
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol (2016) 0.75
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J (2016) 0.75
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol (2016) 0.75
Emerging therapies for acute myeloid leukemia: translating biology into the clinic. JCI Insight (2017) 0.75
VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One (2017) 1.38
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood (2011) 1.30
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood (2009) 1.23
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood (2014) 0.95
Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clin Cancer Res (2015) 0.93
Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nat Immunol (2017) 0.87
Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet (2017) 0.84
Minimal residual disease-directed therapy in acute myeloid leukemia. Blood (2015) 0.84
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biol Blood Marrow Transplant (2016) 0.79
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood (2017) 0.78
Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission. PLoS One (2015) 0.77
Use of hematopoietic cell transplantation for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2017) 0.77
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol (2017) 0.75
Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation. Stem Cells (2015) 0.75
Addition of in-vitro generated endothelial microparticles to von-Willebrand plasma improves primary and secondary hemostasis. Thromb Res (2013) 0.75
Possible Impact of Cytomegalovirus-Specific CD8(+) T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant (2017) 0.75
Human Effector Memory T Helper Cells Engage with Mouse Macrophages and Cause Graft-versus-Host-Like Pathology in Skin of Humanized Mice Used in a Nonclinical Immunization Study. Am J Pathol (2017) 0.75
Successful use of extracorporeal membrane oxygenation during induction chemotherapy in a patient with mediastinal tumor mass of a T lymphoblastic lymphoma. Ann Hematol (2016) 0.75
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant (2017) 0.75